NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations
Alexander Drilon(Memorial Sloan Kettering Cancer Center)
Cited by 45
Related Papers
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
|Nature Communications|2022|110